Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
Identifieur interne : 000830 ( PubMed/Corpus ); précédent : 000829; suivant : 000831Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
Auteurs : Norio Sugaya ; Yuko Sakai-Tagawa ; Masahiro Bamba ; Rieko Yasuhara ; Masahiko Yamazaki ; Chiharu Kawakami ; Yoshio Yamaguchi ; Yoshiaki Ide ; Masataka Ichikawa ; Keiko Mitamura ; Yoshihiro KawaokaSource :
- Antiviral therapy [ 2040-2058 ] ; 2015.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Child, Child, Preschool, Cyclopentanes (therapeutic use), Enzyme Inhibitors (therapeutic use), Female, Fever (drug therapy), Fever (physiopathology), Fever (virology), Guanidines (therapeutic use), Humans, Infant, Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H1N1 Subtype (enzymology), Influenza A Virus, H1N1 Subtype (growth & development), Influenza A Virus, H1N1 Subtype (pathogenicity), Influenza A Virus, H3N2 Subtype (drug effects), Influenza A Virus, H3N2 Subtype (enzymology), Influenza A Virus, H3N2 Subtype (growth & development), Influenza A Virus, H3N2 Subtype (pathogenicity), Influenza, Human (drug therapy), Influenza, Human (physiopathology), Influenza, Human (virology), Male, Neuraminidase (antagonists & inhibitors), Neuraminidase (metabolism), Oseltamivir (therapeutic use), Severity of Illness Index, Time Factors, Treatment Outcome, Viral Proteins (antagonists & inhibitors), Viral Proteins (metabolism), Virus Shedding (drug effects), Zanamivir (analogs & derivatives), Zanamivir (therapeutic use).
- MESH :
- chemical , analogs & derivatives : Zanamivir.
- chemical , antagonists & inhibitors : Neuraminidase, Viral Proteins.
- chemical , metabolism : Neuraminidase, Viral Proteins.
- chemical , therapeutic use : Antiviral Agents, Cyclopentanes, Enzyme Inhibitors, Guanidines, Oseltamivir, Zanamivir.
- drug effects : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Virus Shedding.
- drug therapy : Fever, Influenza, Human.
- enzymology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype.
- growth & development : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype.
- pathogenicity : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype.
- physiopathology : Fever, Influenza, Human.
- virology : Fever, Influenza, Human.
- Child, Child, Preschool, Female, Humans, Infant, Male, Severity of Illness Index, Time Factors, Treatment Outcome.
Abstract
Shedding of the pandemic virus during an influenza pandemic is thought to persist longer than shedding of influenza viruses during annual influenza seasons, because people have much less immunity against a pandemic influenza. A correlation is thought to exist between the length of virus shedding and the clinical severity of influenza illness.
DOI: 10.3851/IMP2798
PubMed: 24832015
Links to Exploration step
pubmed:24832015Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.</title><author><name sortKey="Sugaya, Norio" sort="Sugaya, Norio" uniqKey="Sugaya N" first="Norio" last="Sugaya">Norio Sugaya</name><affiliation><nlm:affiliation>Department of Pediatrics, Keiyu Hospital, Yokohama, Japan. sugaya47@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Sakai Tagawa, Yuko" sort="Sakai Tagawa, Yuko" uniqKey="Sakai Tagawa Y" first="Yuko" last="Sakai-Tagawa">Yuko Sakai-Tagawa</name></author><author><name sortKey="Bamba, Masahiro" sort="Bamba, Masahiro" uniqKey="Bamba M" first="Masahiro" last="Bamba">Masahiro Bamba</name></author><author><name sortKey="Yasuhara, Rieko" sort="Yasuhara, Rieko" uniqKey="Yasuhara R" first="Rieko" last="Yasuhara">Rieko Yasuhara</name></author><author><name sortKey="Yamazaki, Masahiko" sort="Yamazaki, Masahiko" uniqKey="Yamazaki M" first="Masahiko" last="Yamazaki">Masahiko Yamazaki</name></author><author><name sortKey="Kawakami, Chiharu" sort="Kawakami, Chiharu" uniqKey="Kawakami C" first="Chiharu" last="Kawakami">Chiharu Kawakami</name></author><author><name sortKey="Yamaguchi, Yoshio" sort="Yamaguchi, Yoshio" uniqKey="Yamaguchi Y" first="Yoshio" last="Yamaguchi">Yoshio Yamaguchi</name></author><author><name sortKey="Ide, Yoshiaki" sort="Ide, Yoshiaki" uniqKey="Ide Y" first="Yoshiaki" last="Ide">Yoshiaki Ide</name></author><author><name sortKey="Ichikawa, Masataka" sort="Ichikawa, Masataka" uniqKey="Ichikawa M" first="Masataka" last="Ichikawa">Masataka Ichikawa</name></author><author><name sortKey="Mitamura, Keiko" sort="Mitamura, Keiko" uniqKey="Mitamura K" first="Keiko" last="Mitamura">Keiko Mitamura</name></author><author><name sortKey="Kawaoka, Yoshihiro" sort="Kawaoka, Yoshihiro" uniqKey="Kawaoka Y" first="Yoshihiro" last="Kawaoka">Yoshihiro Kawaoka</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:24832015</idno><idno type="pmid">24832015</idno><idno type="doi">10.3851/IMP2798</idno><idno type="wicri:Area/PubMed/Corpus">000830</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000830</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.</title><author><name sortKey="Sugaya, Norio" sort="Sugaya, Norio" uniqKey="Sugaya N" first="Norio" last="Sugaya">Norio Sugaya</name><affiliation><nlm:affiliation>Department of Pediatrics, Keiyu Hospital, Yokohama, Japan. sugaya47@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Sakai Tagawa, Yuko" sort="Sakai Tagawa, Yuko" uniqKey="Sakai Tagawa Y" first="Yuko" last="Sakai-Tagawa">Yuko Sakai-Tagawa</name></author><author><name sortKey="Bamba, Masahiro" sort="Bamba, Masahiro" uniqKey="Bamba M" first="Masahiro" last="Bamba">Masahiro Bamba</name></author><author><name sortKey="Yasuhara, Rieko" sort="Yasuhara, Rieko" uniqKey="Yasuhara R" first="Rieko" last="Yasuhara">Rieko Yasuhara</name></author><author><name sortKey="Yamazaki, Masahiko" sort="Yamazaki, Masahiko" uniqKey="Yamazaki M" first="Masahiko" last="Yamazaki">Masahiko Yamazaki</name></author><author><name sortKey="Kawakami, Chiharu" sort="Kawakami, Chiharu" uniqKey="Kawakami C" first="Chiharu" last="Kawakami">Chiharu Kawakami</name></author><author><name sortKey="Yamaguchi, Yoshio" sort="Yamaguchi, Yoshio" uniqKey="Yamaguchi Y" first="Yoshio" last="Yamaguchi">Yoshio Yamaguchi</name></author><author><name sortKey="Ide, Yoshiaki" sort="Ide, Yoshiaki" uniqKey="Ide Y" first="Yoshiaki" last="Ide">Yoshiaki Ide</name></author><author><name sortKey="Ichikawa, Masataka" sort="Ichikawa, Masataka" uniqKey="Ichikawa M" first="Masataka" last="Ichikawa">Masataka Ichikawa</name></author><author><name sortKey="Mitamura, Keiko" sort="Mitamura, Keiko" uniqKey="Mitamura K" first="Keiko" last="Mitamura">Keiko Mitamura</name></author><author><name sortKey="Kawaoka, Yoshihiro" sort="Kawaoka, Yoshihiro" uniqKey="Kawaoka Y" first="Yoshihiro" last="Kawaoka">Yoshihiro Kawaoka</name></author></analytic><series><title level="j">Antiviral therapy</title><idno type="eISSN">2040-2058</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Child</term><term>Child, Preschool</term><term>Cyclopentanes (therapeutic use)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Female</term><term>Fever (drug therapy)</term><term>Fever (physiopathology)</term><term>Fever (virology)</term><term>Guanidines (therapeutic use)</term><term>Humans</term><term>Infant</term><term>Influenza A Virus, H1N1 Subtype (drug effects)</term><term>Influenza A Virus, H1N1 Subtype (enzymology)</term><term>Influenza A Virus, H1N1 Subtype (growth & development)</term><term>Influenza A Virus, H1N1 Subtype (pathogenicity)</term><term>Influenza A Virus, H3N2 Subtype (drug effects)</term><term>Influenza A Virus, H3N2 Subtype (enzymology)</term><term>Influenza A Virus, H3N2 Subtype (growth & development)</term><term>Influenza A Virus, H3N2 Subtype (pathogenicity)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (physiopathology)</term><term>Influenza, Human (virology)</term><term>Male</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Neuraminidase (metabolism)</term><term>Oseltamivir (therapeutic use)</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term><term>Viral Proteins (antagonists & inhibitors)</term><term>Viral Proteins (metabolism)</term><term>Virus Shedding (drug effects)</term><term>Zanamivir (analogs & derivatives)</term><term>Zanamivir (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Zanamivir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Neuraminidase</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Cyclopentanes</term><term>Enzyme Inhibitors</term><term>Guanidines</term><term>Oseltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term><term>Virus Shedding</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Fever</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Fever</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Fever</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Infant</term><term>Male</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Shedding of the pandemic virus during an influenza pandemic is thought to persist longer than shedding of influenza viruses during annual influenza seasons, because people have much less immunity against a pandemic influenza. A correlation is thought to exist between the length of virus shedding and the clinical severity of influenza illness.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24832015</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2015</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2040-2058</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Antiviral therapy</Title><ISOAbbreviation>Antivir. Ther. (Lond.)</ISOAbbreviation></Journal><ArticleTitle>Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.</ArticleTitle><Pagination><MedlinePgn>49-55</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3851/IMP2798</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Shedding of the pandemic virus during an influenza pandemic is thought to persist longer than shedding of influenza viruses during annual influenza seasons, because people have much less immunity against a pandemic influenza. A correlation is thought to exist between the length of virus shedding and the clinical severity of influenza illness.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We compared the virus isolation rates of children with pandemic A H1N1/09 influenza infection and children with A H3N2 influenza infection after the patients had been treated with one of three neuraminidase inhibitors (NAI) such as peramivir, laninamivir and oseltamivir. The clinical effectiveness of each NAI was assessed on the basis of the duration of the febrile period after the start of treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Influenza viruses were isolated from 15 of the 34 patients in the A H3N2 group (mean age 6.2 years) and from 4 of the 25 patients in the A H1N1/09 (mean age 5.6 years) virus group (44.1% versus 16.0%; P<0.05). However, the differences between the duration of fever in the patients in the A H3N2 group and A H1N1/09 group after treatment with the NAIs were not significant.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The virus isolation rates after treatment with each of the NAIs were significantly lower in the A H1N1/09 group, suggesting that the pandemic A H1N1/09 virus was more sensitive to the NAIs than the seasonal A H3N2 virus was. Clinically, there were no significant differences in the effectiveness of the NAIs between the H1N1/09 infected group and H3N2 infected group.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sugaya</LastName><ForeName>Norio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Keiyu Hospital, Yokohama, Japan. sugaya47@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakai-Tagawa</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Bamba</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yasuhara</LastName><ForeName>Rieko</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Yamazaki</LastName><ForeName>Masahiko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kawakami</LastName><ForeName>Chiharu</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Yoshio</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Ide</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Ichikawa</LastName><ForeName>Masataka</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mitamura</LastName><ForeName>Keiko</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kawaoka</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antivir Ther</MedlineTA><NlmUniqueID>9815705</NlmUniqueID><ISSNLinking>1359-6535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003517">Cyclopentanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006146">Guanidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C546918">R 125489</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6O3XI777I</RegistryNumber><NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>QW7Y7ZR15U</RegistryNumber><NameOfSubstance UI="C414210">peramivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003517" MajorTopicYN="N">Cyclopentanes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006146" MajorTopicYN="N">Guanidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017201" MajorTopicYN="N">Virus Shedding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>05</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24832015</ArticleId><ArticleId IdType="doi">10.3851/IMP2798</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000830 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000830 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24832015
|texte= Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24832015" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |